Day: May 30, 2024

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company. He will continue as an advisor to SAB through the end of the year. The SAB Board of Directors has launched a formal search process to identify Mr. King’s permanent replacement. While this search is underway, Mark Conley, SAB’s current Vice President of Finance and an industry veteran with 38 years of biotech finance and accounting experience, will continue supporting SAB as Interim CFO. “Mike...

Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following the May 27-30 CHMP meeting, Pharming received an updated List of Outstanding Issues (LoOI) from the CHMP. The LoOI affirmed the positive clinical benefit and safety of leniolisib, in agreement with the assessment by the Ad Hoc Expert Group (AEG), and included one remaining chemistry, manufacturing and controls (CMC) request. The CMC request relates to the...

Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20Conference call on Tuesday, June 4, at 4:15 p.m. ETNEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA’s Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET. Complete details and registration information are included below. The call will detail the Company’s Phase 2 clinical data of HB-200 in combination with pembrolizumab for the treatment of human papillomavirus 16 positive head and neck cancer, including preliminary progression-free survival and overall survival...

Company welcomes seasoned finance professional, Kate Walsh, as Vice President, Investor Relations CHICAGO, May 30, 2024 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming waste carbon into sustainable raw materials, today announced that Kate Walsh has joined the Company as Vice President, Investor Relations, effective May 20, 2024. Bringing nearly 15 years of public company investor relations and finance experience to her new role, Ms. Walsh is responsible for driving LanzaTech’s financial communications strategy and engagement with investors and analysts. “Kate is joining LanzaTech at an exciting time, as the Company begins to scale its innovative carbon recycling solutions and pursue step-change growth opportunities in tandem with expanding our customer...

WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, New York, June 6, 2024.Event details:Date: Thursday, June 6, 2024Time: 3:30 pm ETLocation: New York, NY Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the...

NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York. A live webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City...